title: Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.
abstract: Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings.
authors.affiliation: Seattle Children's Research Institute, Seattle, WA, USA.
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Beck
authors.affiliation: Seattle Children's Research Institute, Seattle, WA, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Payant
authors.affiliation: Unité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Ngo-Giang-Huong
authors.affiliation: Unité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
authors.forename: Woottichai
authors.initials: W
authors.lastname: Khamduang
authors.affiliation: Unité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand.
authors.forename: Laddawan
authors.initials: L
authors.lastname: Laomanit
authors.affiliation: Unité Mixte Internationale 174, Institut de Recherche pour le Développement (IRD)-Programs for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.
authors.forename: Gonzague
authors.initials: G
authors.lastname: Jourdain
authors.affiliation: Seattle Children's Research Institute, Seattle, WA, USA; University of Washington, Seattle, WA, USA. Electronic address: lfrenkel@u.washington.edu.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Frenkel
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D003001:Cloning, Molecular; D024882:Drug Resistance, Viral; D005814:Genes, Viral; D005838:Genotype; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009841:Oligonucleotides
chemical_list: D000998:Antiviral Agents; D009841:Oligonucleotides; D019259:Lamivudine
keywords: HBV drug resistance; HBV treatment; Lamivudine resistance; Oligonucleotide ligation assay